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Abstract
Thyroid hormone is essential for normal metabolism and development, and overt abnormalities in thyroid function lead to
common endocrine disorders affecting approximately 10% of individuals over their life span. In addition, even mild
alterations in thyroid function are associated with weight changes, atrial fibrillation, osteoporosis, and psychiatric disorders.
To identify novel variants underlying thyroid function, we performed a large meta-analysis of genome-wide association
studies for serum levels of the highly heritable thyroid function markers TSH and FT4, in up to 26,420 and 17,520 euthyroid
subjects, respectively. Here we report 26 independent associations, including several novel loci for TSH (PDE10A, VEGFA,
IGFBP5, NFIA, SOX9, PRDM11, FGF7, INSR, ABO, MIR1179, NRG1, MBIP, ITPK1, SASH1, GLIS3) and FT4 (LHX3, FOXE1, AADAT,
NETO1/FBXO15, LPCAT2/CAPNS2). Notably, only limited overlap was detected between TSH and FT4 associated signals, in
spite of the feedback regulation of their circulating levels by the hypothalamic-pituitary-thyroid axis. Five of the reported
loci (PDE8B, PDE10A, MAF/LOC440389, NETO1/FBXO15, and LPCAT2/CAPNS2) show strong gender-specific differences, which
offer clues for the known sexual dimorphism in thyroid function and related pathologies. Importantly, the TSH-associated
loci contribute not only to variation within the normal range, but also to TSH values outside the reference range, suggesting
that they may be involved in thyroid dysfunction. Overall, our findings explain, respectively, 5.64% and 2.30% of total TSH
and FT4 trait variance, and they improve the current knowledge of the regulation of hypothalamic-pituitary-thyroid axis
function and the consequences of genetic variation for hypo- or hyperthyroidism.
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Introduction
Through the production of thyroid hormone (TH), the thyroid
is essential for normal development, growth and metabolism of
virtually all human tissues. Its critical role in heart, brain, bone,
and general metabolism is illustrated by the clinical manifestations
of thyroid disease, which affects up to 10% of the population. Low
thyroid function (i.e., hypothyroidism) can lead to weight gain,
high cholesterol, cognitive dysfunction, depression, and cold
intolerance, whereas hyperthyroidism may result in weight loss,
tachycardia, atrial fibrillation, and osteoporosis. Mild variation in
thyroid function, both subclinical and within the normal range, is
associated with these TH-related clinical outcomes as well [1–4].
The thyroid gland secretes predominantly the pro-hormone
thyroxine (T4), which is converted into the active form triiodo-
thyronine (T3) in peripheral tissues. The production of TH by the
thyroid gland is regulated by the hypothalamus-pituitary-thyroid
(HPT) axis, via a so-called negative feedback loop. Briefly, low
levels of serum TH in hypothyroidism result in an increased
release of thyroid stimulating hormone (TSH) by the pituitary,
under the influence of hypothalamic thyrotropin releasing
hormone (TRH) [5]. TSH, a key regulator of thyroid function,
stimulates the synthesis and secretion of TH by the thyroid. When
circulating TH levels are high, as in hyperthyroidism, TRH and
TSH synthesis and secretion are inhibited.
In healthy (euthyroid) individuals, TSH and free T4 (FT4) levels
vary over a narrower range than the broad inter-individual
variation seen in the general population, suggesting that each
person has a unique HPT axis set-point that lies within the
population reference range [6]. Besides environmental factors such
as diet, smoking and medication, little is known about the factors
that influence this inter-individual variation in TSH and FT4
levels [7–9]. The heritability of TSH and FT4 has been estimated
from twin and family studies at about 65% and 40%, respectively
[10–12]. However, the underlying genetic variants are not fully
established, and the contribution of those discovered so far to the
overall variance is modest. Single nucleotide polymorphisms
(SNPs) in the phosphodiesterase type 8B (PDE8B), upstream of the
capping protein (actin filament) muscle Z-line, b (CAPZB) and, more
recently, of the nuclear receptor subfamily 3, group C, member 2 (NR3C2)
and of v-maf musculoaponeurotic fibrosarcoma oncogene homolog (MAF/
LOC440389) genes have been implicated in TSH variation by
genome-wide association studies (GWAS) [13–15], whereas SNPs
in the iodothyronine deiodinase DIO1 have been associated with
circulating levels of TH by candidate gene analysis [16–18].
To identify additional common variants associated with thyroid
function, we performed a meta-analysis of genome-wide associa-
tion data in 26,420 euthyroid individuals phenotyped for serum
TSH and 17,520 for FT4 levels, respectively. In addition, we also
assessed gender-specific effects and correlation with subclinical
thyroid dysfunction.
Results
To identify common genetic variants associated with serum
TSH and FT4 levels, we carried out a meta-analysis of genome-
wide association results from 18 studies for TSH and 15 studies for
FT4 levels, which assessed the additive effect of ,2.5 million
genotyped and HapMap-imputed SNPs in relation to those traits
in individuals of European ancestry (for cohort description see
Table 1 and Table S1). In order to avoid bias due to the presence
of thyroid pathologies, prior to analysis we excluded all individuals
with TSH values outside the normal range (TSH,0.4 mIU/L
and TSH.4.0 mIU/L) and those taking thyroid medication for
known thyroid pathologies whenever the relevant information was
available. Our meta-analysis was thereby carried out in up to
26,420 and 17,520 euthyroid subjects, respectively for TSH and
FT4. Additional exclusion criteria used by individual cohorts are
detailed in Table S1.
Using the standard genome-wide threshold of 561028, we
observed significant associations for SNPs at 23 loci, of which 19
were associated with TSH, and 4 with FT4 (Figure S1). The results
are presented in Table 2 and Figure 1, Figure 2, Figure 3, Figure 4,
Figure 5. In Table S2 single cohort results for each GW significant
SNP are reported.
For TSH, 4 signals confirmed previously described loci with
proxy SNPs at PDE8B (P=1.95610256, r2 = 0.94 with the
reported rs4704397), CAPZB (P=3.60610221, r2 = 1 with the
reported rs10917469) and NR3C2 (P=9.28610216, r2 = 0.90 with
the reported rs10028213), whereas the signal was coincident at
MAF/LOC440389 (P=8.45610218) [13–15]. The remaining
signals were in or near 15 novel loci: PDE10A (phosphodiesterase
type 10A, P=1.21610224), VEGFA (Vascular endothelial growth factor,
P=6.72610216), IGFBP5 (insulin-like growth factor binding protein 5,
P=3.24610215), SOX9 (sex determining region Y-box 9,
P=7.53610213), NFIA (nuclear factor I/A, P=5.40610212), FGF7
(fibroblast growth factor 7, P=1.02610211), PRDM11 (PR domain
containing 11, P=8.83610211), MIR1179 (microRNA 1179,
P=2.89610210), INSR (insulin receptor, P=3.16610210), ABO
(ABO glycosyltransferase, P=4.11610210), ITPK1 (inositol-tetrakispho-
sphate 1-kinase, P=1.7961029), NRG1 (neuregulin 1, P=2.9461029),
MBIP (MAP3K12 binding inhibitory protein 1, P=1.1761028), SASH1
(SAM and SH3 domain containing 1, P=2.2561028), GLIS3 (GLIS
family zinc finger 3, P=2.5561028), (Figure 1, Figure 2, Figure 3,
Figure 4).
For FT4, we confirmed the DIO1 locus (P=7.87610232), with
the same marker previously reported in candidate gene studies
[17,18], and identified 3 additional novel loci, LHX3 (LIM homeobox
3, P=2.30610214), FOXE1 (forkhead box E1, P=1.50610211) and
AADAT (aminoadipate aminotransferase, P=5.2061029) (Figure 5).
The most associated SNP at the FOXE1 locus, rs7045138, is a
surrogate for rs1443434(r2 = 0.97), previously only suggestively
associated with FT4 levels [18], and is also correlated with SNPs
recently reported to be associated with both low serum TSH and
FT4 levels (r2 = 0.59 with rs965513) [19], as well as with
hypothyroidism (r2 = 0.59 with rs7850258) [20].
At each locus, a single variant was sufficient to explain entirely
the observed association, except for the VEGFA locus, which
contained an independent signal located 150 kb downstream of
the gene, detected by conditional analyses (Figure 1F and Table 2).
Genetic Regulation of Thyroid Function
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Of all 24 independent markers, significant evidence for
heterogeneity (P,0.002, corresponding to a Bonferroni threshold
of 0.5/24) was only observed at ABO (P=1.2261024). Iodine
nutrition, which may profoundly affect thyroid function, is quite
different in some of the cohorts under study (i.e., Europe vs North
America). To test whether the observed heterogeneity could be
attributable to different iodine intake, we combined cohorts from
South Europe (an iodine-deficient region) and compared effect
sizes with those observed in a meta-analysis of North American
samples (an iodine-replete region). Interestingly, the effect size of
the top marker at ABO was three times larger in Europeans vs
North American, and this difference remained significant after
Bonferroni correction (P=7.0.961024) (Table S3). However, the
relation of the ABO SNP, a tag for the blood group O, to iodine
intake remains to be determined.
Gender-specific analyses
Given the reported clinical differences in thyroid function in
males and females [21–23], we searched for gender-specific loci by
whole-genome sex-specific meta-analysis, analyzing males and
females separately in each cohort. Some of the loci detected in the
main meta-analysis were seen at genome-wide significance level
only in females (NR3C2, VEGFA, NRG1 and SASH1) or in males
(MAF/LOC440389, FGF7, SOX9, IGFBP5) with either the same
top SNP or one surrogate, but effect sizes at their variants were
significantly gender-specific only at PDE8B, PDE10A and MAF/
LOC440389, considering a false discovery rate of 5% [24]. In
addition, effects at MAF/LOC440389 were significantly different
also at the more stringent Bonferroni threshold of 1.961023
( = 0.05/26), and close to significance at PDE8B and PDE10A
(Table 3). At these latter loci, the TSH-elevating alleles showed a
stronger impact on trait variability in males compared to females
(Figure 6). In addition, the gender specific meta-analysis for FT4,
revealed a novel female-specific locus on chromosome 18q22, and
a novel male-specific locus on chromosome 16q12.2, that had not
been detected in the main meta-analysis (Table 3, Figure 6 and
Figure S2). The female-specific signal (rs7240777, P=3.4961028)
maps in a ‘‘gene desert’’ region, with the nearest genes NETO1
(neuropilin (NRP) and tolloid (TLL)-like 1), located, about 550 kb
upstream and FBXO15 (F-box only protein 15) 500 kb downstream
(Figure 5D). The male-specific association is located in intron 11 of
the LPCAT2 (lysophosphatidylcholine acyltransferase 2) gene, and near
CAPNS2 (calpain, small subunit 2) (rs6499766, P=4.6361028), a
gene which may play a role in spermatogenesis [25]. The FT4-
elevating alleles in the NETO1/FBXO15 and LPCAT2/CAPNS2
were fully gender-specific, i.e. there was no effect in males and in
females, respectively (P.0.01).
Overall, the 20 TSH and the 6 FT4 associations account,
respectively, for 5.64% and 2.30% of total trait variance.
Common loci regulating TSH and FT4 levels
To explore overlap between TSH- and FT4-associated loci and
their involvement in the HPT-negative feedback loop, we assessed
the associations of the top TSH-associated SNPs on FT4 levels,
and vice versa. For the SNPs in or near PDE8B, MAF/LOC440389,
VEGFA, IGFBP5, NFIA, MIR1179, MBIP and GLIS3 the TSH-
elevating allele appeared to be associated with decreasing FT4
levels (P,0.05, Table S4). However, after application of
Bonferroni correction (threshold for FT4 association of TSH
SNPs, P=2.561023), none of these reciprocal associations
remained significant.
By contrast, a positive relationship was seen for one of the FT4
associated loci, since the variant at the LHX3 locus was
significantly associated with higher levels of both FT4 and TSH
(P=5.2561023, with Bonferroni threshold 0.05/6= 0.008).
As the presence of reciprocal associations between TSH and
FT4 regulating SNPs would be expected from physiology, we
tested the power of our study to detect such a relationship. Power
calculation for the top SNP at PDE8B, which has the largest effect
on TSH levels, revealed that our meta-analysis only has 9% power
to detect an association of FT4 at a Bonferroni P=2.561023. We
also carried out a bivariate analysis in the SardiNIA study using
poly software to estimate specific contributions [26]. This analysis
showed that most of the observed negative feedback correlation is
due to environmental factors (environmental correla-
tion=20.130, genetic correlation=20.065).
Association of loci with hypothyroidism and
hyperthyroidism
To assess possible clinical implications, we investigated whether
the variants identified in individuals without overt thyroid
pathologies (i.e., with TSH levels within the normal range and
not taking thyroid medication) were also associated in individuals
with abnormal TSH values (i.e., outside the reference range), who
were not included in the initial meta-analysis as potentially affected
by thyroid pathology. Towards this, we first assessed the global
impact of TSH- and FT4-associated SNPs on the risk of increased
or decreased TSH levels by comparing weighted genotype risk
score (GRS) quartiles in the individuals with abnormal TSH values
that were discarded for the GWAS analyses. For the TSH-
associated SNPs, the odds of increased TSH levels were 6.65 times
greater in individuals with a GRS in the top quartile compared to
individuals in the bottom quartile (P=3.43610220) (Table 4, top
panel, lower vs upper tail). When we compared subjects with high
TSH values with subjects within the normal TSH reference range,
subjects with a GRS in the top quartile had odds of an elevated
TSH 2.37 times greater than for subjects in the bottom quartile
(P=1.06610217) (Table 4). With regard to low TSH values versus
the normal range, the odds ratio was 0.26 (P=5.43610213)
(Table 4, top panel, lower vs normal tail). By contrast, with the
Author Summary
Levels of thyroid hormones are tightly regulated by TSH
produced in the pituitary, and even mild alterations in
their concentrations are strong indicators of thyroid
pathologies, which are very common worldwide. To
identify common genetic variants associated with the
highly heritable markers of thyroid function, TSH and FT4,
we conducted a meta-analysis of genome-wide association
studies in 26,420 and 17,520 individuals, respectively, of
European ancestry with normal thyroid function. Our
analysis identified 26 independent genetic variants regu-
lating these traits, several of which are new, and confirmed
previously detected polymorphisms affecting TSH (within
the PDE8B gene and near CAPZB, MAF/LOC440389, and
NR3C2) and FT4 (within DIO1) levels. Gender-specific
differences in the genetic effects of several variants for
TSH and FT4 levels were identified at several loci, which
offer clues to understand the known sexual dimorphism in
thyroid function and pathology. Of particular clinical
interest, we show that TSH-associated loci contribute not
only to normal variation, but also to TSH values outside
reference range, suggesting that they may be involved in
thyroid dysfunction. Overall, our findings add to the
developing landscape of the regulation of thyroid
homeostasis and the consequences of genetic variation
for thyroid related diseases.
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FT4-associated SNPs we found no significant associations for any
of the tested comparisons (data not shown).
We also assessed the 20 independent TSH SNPs individually in
relation to the risk of abnormal TSH levels by case-control meta-
analysis in subjects with high (cases) versus low (controls) TSH
values. This analysis showed that variants at PDE8B, CAPZB,
FGF7, PDE10A, NFIA and ITPK1 loci are significantly associated
(Bonferroni threshold P=2.561023) with abnormal TSH levels
(Table 4, bottom panel). PDE8B, CAPZB and FGF7 were also
strongly associated with the risk of decreased TSH levels in an
analysis of individuals with low (cases) versus normal range TSH
(controls). In addition, variants at VEGFA were also significantly
associated in this comparison. Finally, when individuals with high
TSH values were analyzed versus controls, the NR3C2 locus
appeared significantly associated in addition to PDE8B and
CAPZB.
Association of TSH lead SNPs in pregnant women
Normal thyroid function is particularly important during
pregnancy and elevated TSH levels are implicated in a number
of adverse outcomes for both mother and offspring. We therefore
assessed whether the TSH lead SNPs were also associated with
elevated TSH during pregnancy, when increased TH production
is necessary. We tested 9 of the 20 lead TSH variants (or their
proxies, see Text S1) in a cohort of 974 healthy pregnant women
at 28 weeks gestation [27] and found, as expected, that mean TSH
levels were correlated with the number of TSH-elevating alleles
(P=3.0610212, Table S5). Effect size estimates in pregnant
women were not significantly different when compared to those of
women in the main gender-specific meta-analysis (heterogeneity P
value.0.05), suggesting that the effects of the TSH-elevating
alleles are no greater during pregnancy (data not shown).
However, there was evidence of association between the number
of TSH-raising alleles and subclinical hypothyroidism in pregnan-
cy, both in the whole sample (OR per weighted allele: 1.18
[95%CI: 1.01, 1.37], P=0.04) and in TPO antibody-negative
women (1.29 [95%CI: 1.08, 1.55], P=0.006) (Table S6).
Discussion
We report 26 independent SNPs associated with thyroid
function tests in euthyroid subjects, 21 of which represent novel
signals (16 for TSH and 5 for FT4). Overall they explain 5.64%
and 2.30% of the variation in TSH and FT4 levels, respectively.
We observed that carriers of multiple TSH-elevating alleles
have increased risk of abnormal TSH levels, and also found
association between the number of TSH-elevating alleles and
subclinical hypothyroidism in pregnancy. These results are
potentially clinically relevant, because abnormal TSH values are
the most sensitive diagnostic markers for both overt and subclinical
thyroid disease [4]. The variants identified in the current study, or
those in LD with them, may thus contribute to the pathogenesis of
thyroid disease. Of note, we found eight loci significantly
associated with abnormal TSH levels (PDE8B, PDE10, CAPZB,
VEGFA, NR3C2, FGF7, NFIA and ITPK1), of which two were
specifically associated with either abnormally low (VEGFA) or
elevated (NR3C2) TSH values, suggesting differential mechanisms
for the contribution of these variants to hyper- and hypothyroid-
ism, respectively. Interestingly, the mineralocorticoid receptor
NR3C2 gene has recently been found to be up-regulated in adult-
onset hypothyroidism [28], and PDE8B and CAPZB have been
suggestively associated with hypothyroidism by GWAS [29].
Alternatively, it may be that carriers of these alleles are healthy
individuals who may be misdiagnosed as having thyroid disease
because their genetically determined TSH concentrations fall
outside the population-based reference range. More research is
required to determine which of these interpretations is correct, and
the relevance of these variants as markers for thyroid dysfunction
or thyroid-related clinical endpoints.
Table 1. Descriptive statistics of all cohorts.
Cohort Subjects (N) Age, mean (SD) Age (range) Men (%) TSH, mean (SD) FT4, mean (SD)
BLSA 593 69.9 (15.4) 22–98 54.8 2.1 (0.9) 1.1 (0.2)
CHS 1,655 74.6 (4.9) 67–94 41.8 2.1 (0.9) 1.2 (0.2)
FHS 2,140 47.4 (10.0) 21–77 49.9 1.6 (0.8) NA
GARP 290 60.3 (7.5) 42–79 20.3 1.9 (0.8) 1.2 (0.2)
HBCS 454 60.9 (2.8) 56–68 51.3 1.8 (0.8) 1.1 (0.1)
InChianti 951 68.4 (15.4) 21–102 45.3 1.5 (0.8) 1.4 (0.3)
LBC1921 401 79.0 (0.6) 77–80 44.0 1.7 (0.8) 1.1 (0.2)
LBC1936 834 69.5 (0.8) 67–71 54.0 1.7 (0.8) 1.2 (0.2)
LifeLines 1,306 45.0 (10.0) 20–79 44.6 2.7 (4.1) 1.3 (0.2)
LLS 736 59.1 (6.8) 30–75 45.9 1.7 (0.8) 1.2 (0.2)
MICROS 1,047 44.6 (16.5) 8–94 45.7 1.9 (0.9) 1.0 (0.2)
NBS 1,617 61.5 (10.3) 27–78 50.7 1.6 (1.1) 1.1 (0.2)
OOA 1,025 49.9 (16.7) 20–97 57.8 2.2 (0.5) NA
PROSPER 4,402 75.3 (3.4) 69–83 49.1 1.9 (0.8) 1.3 (0.2)
RS 1,346 68.7 (7.4) 55–93 40.7 1.6 (0.8) 1.3 (0.2)
SardiNIA 4,087 42.5 (17.7) 14–101 46.9 1.7 (0.8) 1.3 (0.2)
TwinsUK 2,133 46.6 (12.5) 18–82 0 1.4 (0.7) 1.1 (0.1)
ValBorbera 1,403 53.6 (18.3) 18–102 46.9 1.5 (0.8) NA
The table shows descriptive statistics of all cohorts included in the meta-analysis. TSH is reported in mIU/L and FT4 in ng/dl. SD, standard deviation.
doi:10.1371/journal.pgen.1003266.t001
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The evidence for gender-specific differences at several TSH and
FT4 regulatory loci is intriguing. They included variants at PDE8B,
PDE10A, and MAF/LOC440389, which showed significantly stronger
genetic effects with pituitary-thyroid function in males, and variants at
NETO1/FBX015 and LPCAT2/CAPNS2which seems to have an effect
only in females and males, respectively. Sex differences in the
regulation of thyroid function have generally been linked to the
influence of sex hormones and autoimmune thyroid disease, resulting
in a higher prevalence of thyroid dysfunction in women, without clear
understanding of underlying molecular mechanisms [21–23]. Our
study suggests that differential genes and mechanisms are potentially
implicated in the regulation of thyroid function in men and women.
Given the impact of thyroid function on several disease outcomes as
well as male and female fertility and reproduction, clarifying the
underlying associations may provide additional insight for future
interventions.
Although it is well known that TSH and FT4 levels are tightly
regulated through a negative feedback loop involving the HPT
axis, we detected significant overlap between TSH and FT4
signals only at the LHX3 locus, which was primarily associated in
our study with FT4. The LHX3 allele is associated with an
increase of both TSH and FT4, which is consistent with the
essential role of this transcription factor in pituitary development.
Inactivating mutations in LHX3 cause the combined pituitary
hormone deficiency-3 syndrome [CPHD3 (MIM#221750)]
[30,31], characterized by low TSH and FT4 levels. The positive
association of the LHX3 variant with both TSH and FT4 suggests
an effect of this allele at the level of the HPT-axis, resulting in an
increased exposure to thyroid hormone throughout life. In
contrast, although several of the TSH-elevating alleles appeared
to be associated with decreasing FT4 levels, none of these
reciprocal associations remained significant after Bonferroni
correction. Lack of loci associated in a reciprocal manner with
both TSH and FT4 is somewhat puzzling, as their presence
would be expected from physiology. However, these findings are
consistent with initial reports by Shields et al. [27] and more
Table 2. Independent SNPs associated with TSH and FT4 serum levels.
Gene SNP Chr Position A1/A2 Freq A1 Effect StdErr P N Het P
TSH levels
PDE8B rs6885099 5 76566105 A/G 0.594 20.141 0.009 1.95610256 26042 0.520
PDE10A rs753760 6 165966473 C/G 0.691 0.100 0.010 1.21610224 25988 0.363
CAPZB rs10799824 1 19713761 A/G 0.161 20.113 0.012 3.60610221 26031 0.042
MAF/LOC440389 rs3813582 16 78306854 T/C 0.674 0.082 0.010 8.45610218 25948 0.292
VEGFA rs9472138 6 43919740 T/C 0.285 20.079 0.010 6.72610216 25767 0.017
VEGFA rs11755845 6 44012758 T/C 0.266 20.065 0.010 1.68610210 25710 0.417
NR3C2 rs10032216 4 149888956 T/C 0.781 0.087 0.011 9.28610216 26053 0.504
IGFBP5 rs13015993 2 217333768 A/G 0.736 0.078 0.010 3.24610215 26016 0.605
SOX9 rs9915657 17 67639131 T/C 0.541 20.064 0.009 7.53610213 25692 0.349
NFIA rs334699 1 61393084 A/G 0.052 20.141 0.021 5.40610212 25757 4.0561023
FGF7 rs10519227 15 47533656 A/T 0.245 20.072 0.011 1.02610211 25988 0.098
PRDM11 rs17723470 11 45184143 T/C 0.279 20.065 0.010 8.83610211 26054 0.833
MIR1179 rs17776563 15 86920108 A/G 0.322 20.060 0.010 2.89610210 25758 0.452
INSR rs4804416 19 7174848 T/G 0.569 20.057 0.009 3.16610210 25632 0.438
ABO rs657152 9 135129086 A/C 0.343 0.058 0.009 4.11610210 25765 1.2261024
ITPK1 rs11624776 14 92665344 A/C 0.660 20.064 0.011 1.7961029 23482 0.845
NRG1 rs7825175 8 32535816 A/G 0.210 20.066 0.011 2.9461029 25996 0.711
MBIP rs1537424 14 35643769 T/C 0.608 20.052 0.009 1.1761028 25478 0.333
SASH1 rs9497965 6 148562985 T/C 0.415 0.051 0.009 2.2561028 25980 0.444
GLIS3 rs1571583 9 4257209 A/G 0.249 0.057 0.010 2.5561028 25766 0.118
FT4 levels
DIO1 rs2235544 1 54148158 A/C 0.510 0.138 0.012 7.87610232 17226 0.193
LHX3 rs7860634 9 138229500 A/G 0.530 0.102 0.013 2.30610214 14529 0.067
FOXE1 rs7045138 9 99631284 T/C 0.553 0.098 0.015 1.50610211 10997 0.457
AADAT rs11726248 4 171290094 A/G 0.106 0.111 0.019 5.2061029 17515 0.972
LPCAT2/CAPNS2 rs6499766 16 54161629 A/T 0.478 0.056 0.012 1.1861026 17489 0.269
NETO1/FBXO15 rs7240777 18 69318732 A/G 0.5632 20.049 0.012 3.1361025 17146 7.8461023
The table shows the association results for SNPs that reached genome-wide level (p,5610208) in the main meta-analysis. SNPs at LPCAT2/CAPNS2 and NETO1/FBXO15
reached the GW threshold in the gender-specific meta analysis (see Table 3), and here the p-value in the main meta-analysis is reported. For each SNP, the best
candidate gene is showed, as well as its genomic position in build 36, the effect allele (A1) and the other allele (A2), its combined frequency across studies and its
standard error, the effect size and its standard error, the p-value for association, the number of samples analyzed, and the p-values for heterogeneity of effects across
the cohorts meta-analyzed. Effect sizes are standardized, so they represent the estimated phenotypic change, per each copy of the effect allele, in standard deviation
units.
doi:10.1371/journal.pgen.1003266.t002
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recent findings by Gudmundsson et al. [32]. A power analysis
showed that our study – in spite of being one of the larger
conducted so far on these traits – is underpowered to detect an
inverse relationship between TSH and FT4 variants, considering
a Spearman rank correlation of 20.130 between these traits [12].
As a consequence, contrasting studies on smaller sample sizes
may also lack power and cannot be considered robust when
testing this relationship [33]. In addition, we estimated that most
of the observed negative feedback correlation is due to
environmental factors; so it is unlikely that negative feedback is
controlled by a genetic locus with large effect. This observation
can rationalize the lack of reciprocal, significant associations
Figure 1. Regional association plots showing genome-wide significant loci for serum TSH. In each panel (A–F), the most significant SNP is
indicated (purple circle). In panel F, an independent signal at the associated locus is indicated with an arrow. The SNPs surrounding the most
significant SNP are color-coded to reflect their LD with this SNP as in the inset (taken from pairwise r2 values from the HapMap CEU database build
36/hg18). Symbols reflect genomic functional annotation, as indicated in the legend [61]. Genes and the position of exons, as well as the direction of
transcription, are noted in lower boxes. In each panel the scale bar on the Y-axis changes according to the strength of the association.
doi:10.1371/journal.pgen.1003266.g001
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detected for both TSH and FT4 in this and other studies, and
further supports the crucial role of the HPT-axis in maintaining
normal levels of thyroid hormone.
At present the relationship between the associated variants and
specific mechanisms involved in regulating TSH and FT4 levels
has not been established, but we have identified strong candidates
at the majority of the loci by literature-mining approaches, as
detailed below and in Table 5.
Most of the 16 novel loci implicated in the regulation of TSH
are highly represented in the thyroid with the exception of
PRDM11, expressed in brain, ABO, in blood, and MIR1179.
PDE10A encodes a cAMP-stimulated phosphodiesterase, which
Figure 2. Regional association plots showing genome-wide significant loci for serum TSH. In each panel (A–F), the most significant SNP is
indicated (purple circle). The SNPs surrounding the most significant SNP are color-coded to reflect their LD with this SNP as in the inset (taken from
pairwise r2 values from the HapMap CEU database build 36/hg18). Symbols reflect genomic functional annotation, as indicated in the legend [61].
Genes and the position of exons, as well as the direction of transcription, are noted in lower boxes. In each panel the scale bar on the Y-axis changes
according to the strength of the association.
doi:10.1371/journal.pgen.1003266.g002
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was previously only suggestively associated with TSH levels and
hypothyroidism [13,34], although the tested variants were weakly
correlated with our top signal (r2 = 0.55 with rs2983521 and
r2 = 0.15 with rs9347083). The presence of linkage at this gene in
families reaching accepted clinical criteria of thyroid dysfunction
reinforces the observation that variants in this gene may contribute
to clinical thyroid disorders [34]. PDE10A, together with PDE8B
and CAPZB, emerged in our study as the strongest currently
known genetic determinants of this trait. Both PDE8B and
PDE10A are implicated in cAMP degradation in response to
TSH stimulation of thyrocytes. In addition, the activity of both
PDE10A and CAPZB appear modulated by cAMP [35,36]. These
Figure 3. Regional association plots showing genome-wide significant loci for serum TSH. In each panel (A–F), the most significant SNP is
indicated (purple circle). The SNPs surrounding the most significant SNP are color-coded to reflect their LD with this SNP as in the inset (taken from
pairwise r2 values from the HapMap CEU database build 36/hg18). Symbols reflect genomic functional annotation, as indicated in the legend [61].
Genes and the position of exons, as well as the direction of transcription, are noted in lower boxes. In each panel the scale bar on the Y-axis changes
according to the strength of the association.
doi:10.1371/journal.pgen.1003266.g003
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three genes most likely act in a pathway that leads to cAMP-
dependent thyroid hormone synthesis and release, thus highlight-
ing a critical role of cAMP levels in thyroid function. For the other
TSH-associated loci (VEGFA, IGFBP5, SOX9, NFIA, FGF7,
PRDM11, MIR1179, INSR, ABO, ITPK1, NRG1, MBIP, SASH1
and GLIS3), hypotheses can be formulated based on the published
literature (see Table 5), but further studies will be necessary to
clarify the exact biological mechanisms and the specific genes
involved at each locus. The association of TSH levels with
IGFBP5, INSR and NR3C2 is, however, an indication of a specific
role of the growth hormone/insulin-like growth factor (GH/IGF)
pathway in thyroid function. Remarkably, expression of IGFBP5 is
tightly regulated by cAMP, again underlying the pivotal role of this
second messenger in determining net TSH levels [37].
For FT4, the DIO1, FOXE1 and LHX3 identified loci have
strong biological support as potential effectors. While both DIO1
and FOXE1 were previously associated with FT4 levels and
hypothyroidism by candidate gene analysis and functional studies
[17–19,38–41], association at LHX3 is novel and is consistent with
the essential role of this transcription factor in pituitary
development (see above) [30,31,42,43]. Consistent with the role
of pituitary in growth, this locus has also recently been associated
with height in Japanese [44]. The associations of AADAT, NETO1/
FXBO15 and LPCT2/CAPNS2 with FT4 levels are currently less
clear. It may be relevant that AADAT catalyzes the synthesis of
kynurenic acid (KYNA) from kynurenine (KYN), a pathway that
has been associated with the induction in brain of proinflamma-
tory cytokines that are known to activate the hypothalamo-
pituitary-adrenal (HPA) axis, in turn affecting the HPT axis and
thyroid function, including FT4 levels [45–49].
Additional pathway analyses by MAGENTA [50], GRAIL
[51], and IPA (Ingenuity Systems, www.ingenuity.com) to look for
functional enrichment of the genes mapping to the regions
associated with TSH, FT4 or both, yielded no novel interactions.
However, IPA highlighted an over-representation of genes
implicated in developmental processes (11/26, P=6.2761026–
8.8561023) and cancer (16/26 loci, P=2.4461026–9.3061023).
This is consistent with the notion that a normally developed
thyroid gland is essential for both proper function and thyroid
hormone synthesis, and that defects in any of the essential steps in
thyroid development or thyroid hormone synthesis may result in
morphologic abnormalities, impaired hormonogenesis and growth
dysregulation. It is also interesting to note that 11 of the 20 TSH
signals and 3 of the 6 FT4 signals are connected in a single protein
network, underlying the biological interrelationship between genes
regulating these traits (Figure S3).
While our manuscript was in preparation, a GWAS of
comparable sample size was published on levels of TSH in the
general Icelandic population, which confirmed 15 of our reported
loci (E. Porcu et al., 2011, ESHG, abstract), and inferred a role for
three TSH-lowering variants in thyroid cancer [32]. Four
additional TSH loci identified by Gudmundsson and colleagues
were also associated in our sample-set of euthyroid individuals
with p,0.05 and consistent direction of effects (VAV3, NKX2–3,
TPO and FOXA2). Finally, 2 loci (SIVA1, ELK3) could not be tested
because the corresponding SNPs or any surrogate (r2.0.5) were
not available in our data set (Table S7). Our study shows that most
of the loci described in Icelanders are reproducible in other
populations of European origin; differences in sample size,
phenotype definition (i.e., selection of euthyroid subjects vs general
population) and in the genetic map used to detect associations
most likely explain non-overlapping genome-wide significant
signals. Among them, the reported signals at SOX9, ABO, SASH1,
GLIS3 and MIR1179 will need to be confirmed in other studies;
but one of them - GLIS3- is a prime candidate, because it is
involved in congenital hypothyroidism [52]. Interestingly, despite
the use of variants detected through whole-genome sequencing in
Icelanders, the top signals at seven overlapping loci (PDE8B,
PDE10A, CAPZB, MAF/LOC440389, VEGFA, NR3C2, IGFBP5)
were either coincident or in high LD (r2.0.9) with those detected
in our HapMap-based meta-analysis. Thus, such variants are likely
to be the causative ones.
In conclusion, our study reports the first GWAS meta-analysis
ever carried out on FT4 levels, adds to the existing knowledge
novel TSH- and FT4-associated loci and reveals genetic factors
that differentially affect thyroid function in males and females.
Figure 4. Regional association plots showing genome-wide significant loci for serum TSH. In the upper panel, the most significant SNP is
indicated (purple circle). The SNPs surrounding the most significant SNP are color-coded to reflect their LD with this SNP as in the inset (taken from
pairwise r2 values from the HapMap CEU database build 36/hg18). Symbols reflect genomic functional annotation, as indicated in the legend [61].
Genes and the position of exons, as well as the direction of transcription, are noted in the lower box. The scale bar on the Y-axis changes according to
the strength of the association.
doi:10.1371/journal.pgen.1003266.g004
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Several detected loci have potential clinical relevance and have
been previously implicated both in Mendelian endocrine disorders
(LHX3 [MIMM#221750], FOXE1 [MIMM#241850], PDE8B
[MIMM#614190], NR3C2 [MIMM#177735], INSR [MIMM
#609968], GLIS3 [MIMM#610199]) and thyroid cancer (FOXE1
[19], VEGFA [53], IGFBP5 [54], INSR [55], NGR1 [32], MBIP
[32], FGF7 [56]). Furthermore, the TSH-associated variants were
found to contribute to TSH levels outside the reference range.
Overall, our findings add to the developing landscape of the
regulation of hypothalamic-pituitary-thyroid axis function and
the consequences of genetic variation for hypo- or hyperthyroid-
ism.
Figure 5. Regional association plots showing genome-wide significant loci for serum FT4. In each panel (A–F), the most significant SNP is
indicated (purple circle). The SNPs surrounding the most significant SNP are color-coded to reflect their LD with this SNP as in the inset (taken from
pairwise r2 values from the HapMap CEU database build 36/hg18). Symbols reflect genomic functional annotation, as indicated in the legend [61].
Genes and the position of exons, as well as the direction of transcription, are noted in lower boxes. In each panel the scale bar on the Y-axis changes
according to the strength of the association.
doi:10.1371/journal.pgen.1003266.g005
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Methods
Ethics statement
All human research was approved by the relevant institutional
review boards, and conducted according to theDeclaration of Helsinki.
Cohort details
Cohort description, genotyping and statistical methods for
individual study cohorts are reported in Text S1 and Table S1.
Statistical analyses
We carried out a meta-analysis including up to 26,523,
individuals from 18 cohorts for TSH and up to 17,520 individuals
from 15 cohorts for FT4 (see Table 1). FT4 measures were not
available for all 21,955 individuals with TSH levels of the 15
participating cohorts. We combined evidence of associations from
single GWAS using an inverse variance meta-analysis, where
weights are proportional to the squared standard error of the beta
estimates, as implemented in METAL [57]. Prior to GWAS, each
study excluded individuals with known thyroid pathologies, taking
thyroid medication, who underwent thyroid surgery, and with out-
of-range TSH values (,0.4 mIU/L and .4 mIU/L), and an
inverse normal transformation was applied to each trait (Table
S1). Age, age-squared, and gender were fitted as covariates, as well
as principal components axes or additional variables, as required
(Table S1). Family-based correction was applied if necessary (see
Table S1). Uniform quality control filters were applied before
meta-analysis, including MAF ,0.01, call rate ,0.9, HWE
P,161026 for genotyped SNPs and low imputation quality
(defined as r2,0.3 or info ,0.4 if MACH [58] or IMPUTE
[59,60] were used, respectively) for imputed SNPs.
Genomic control was applied to individual studies if lambda was
.1.0. The overall meta-analysis showed no significant evidence
for inflated statistics (lambda for TSH, FT4 and were 1.05 and
1.03 respectively). To evaluate for heterogeneity in effect sizes
across populations, we used a chi-square test for heterogeneity,
Table 3. Top associated SNPs and their effect on males and females separately.
Females Males
Gene SNP A1/A2 Effect StdErr P N Effect StdErr P N Het P FDRs
TSH levels
PDE8B rs6885099 A/G 20,120 0.012 6.09610224 14509 20.168 0.013 2.70610238 11533 7.1261023 0.037
PDE10A rs753760 C/G 0.076 0.013 4.6461029 14473 0.131 0.014 5.85610220 11515 5.4061023 0.035
CAPZB rs10799824 A/G 20.123 0.016 2.69610214 14504 20.099 0.017 1.1761028 11527 0.309 0.618
MAF/LOC440389 rs3813582 T/C 0.055 0.013 1.7561025 14449 0.115 0.014 6.17610217 11499 1.5061023 0.019
VEGFA rs9472138 T/C 20.090 0.013 6.30610212 14291 20.065 0.014 4.8961026 11476 0.208 0.450
VEGFA rs11755845 T/C 20.058 0.014 1.9861025 14250 20.076 0.015 2.9861027 11460 0.368 0.683
NR3C2 rs10032216 T/C 0.106 0.014 1.72610213 14519 0.069 0.016 1.1261025 11534 0.092 0.294
IGFBP5 rs13015993 A/G 0.069 0.013 1.7161027 14491 0.095 0.015 7.60610211 11525 0.193 0.450
SOX9 rs9915657 T/C 20.063 0.012 1.4661027 14241 20.068 0.013 2.3961027 11451 0.793 0.896
NFIA rs334699 A/G 20.143 0.027 1.8061027 14253 20.149 0.030 5.9361027 11504 0.874 0.909
FGF7 rs10519227 A/T 20.051 0.014 3.8061024 14462 20.095 0.015 6.09610210 11526 0.036 0.156
PRDM11 rs17723470 T/C 20.069 0.013 2.9261027 14519 20.056 0.015 1.4561024 11535 0.519 0.710
MIR1179 rs17776563 A/G 20.053 0.013 3.7061025 14305 20.069 0.014 6.1661027 11453 0.395 0.684
INSR rs4804416 T/G 20.058 0.012 1.7661026 14205 20.058 0.013 1.1261025 11427 0.969 0.969
ABO rs657152 A/C 0.054 0.013 1.3161025 14290 0.067 0.014 1.0161026 11475 0.498 0.710
ITPK1 rs11624776 A/C 20.053 0.015 3.2961024 12255 20.069 0.015 2.6161026 11227 0.453 0.693
NRG1 rs7825175 A/G 20.084 0.015 1.6461028 14475 20.049 0.016 2.3661023 11521 0.113 0.294
MBIP rs1537424 T/C 20.054 0.012 1.2661025 14091 20.050 0.013 1.5961024 11387 0.848 0.909
SASH1 rs9497965 T/C 0.067 0.012 3.3661028 14462 0,031 0.013 0.023 11518 0.046 0.171
GLIS3 rs1571583 A/G 0.041 0.014 2.8661023 14290 0.074 0.015 9.8261027 11476 0.104 0.294
FT4 levels
DIO1 rs2235544 A/C 0.130 0.015 2.62610218 10019 0.143 0.018 4.59610215 7201 0.605 0.786
LHX3 rs7860634 A/G 0.098 0.018 5.0161028 7665 0.108 0.019 1.7261028 6864 0.715 0.845
FOXE1 rs7045138 T/C 0.093 0.020 3.1061026 5801 0.105 0.021 4.9661027 5196 0.679 0.840
AADAT rs11726248 A/G 0.123 0.024 4.0361027 10252 0.093 0.029 1.4761023 7263 0.440 0.693
LPCT2/CAPNS2 rs6499766 A/T 0.030 0.015 0.040 10231 0.099 0.018 4.6361028 7258 3.4261023 0.029
NETO1/FBXO15 rs7240777 A/G 20.083 0.015 3.4961028 9963 20.001 0.018 0.950 7183 5.6461024 0.014
The table shows the association results in males and females separately for all independent SNPs associated with TSH and FT4 in the main meta-analysis (Table 2), as
well as for the marker found to be associated only in females in the gender-specific meta-analysis. The last two columns report the p-value (Het P) and the false
discovery rates (FDRs) for differences of effect sizes. SNPs with significantly different effect sizes at 5% FDRs and/or Bonferroni threshold (p = 1.961023) are highlighted
in bold. SdtErr, standard error; A1, effect allele; A2 other allele.
doi:10.1371/journal.pgen.1003266.t003
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implemented in METAL [57]. The same test was used to evalute
heterogeneity related to iodine intake, by comparing effect sizes
obtained in a meta-analysis of studies assessing individuals from
South Europe (InChianti, MICROS, Val Borbera, SardiNIA,
totaling up to 7,488 subjects) with those estimated in a meta-
analysis of studies assessing individuals from North America
(BLSA, CHS, FHS, OOA, totaling up to 5,407 subjects). Finally,
the main meta-analysis was carried out independently by two
analysts who obtained identical results.
Conditional analysis
To identify independent signals, each study performed GWA
analyses for both TSH and FT4 by adding the lead SNPs found in
the primary analysis (19 for TSH, and 4 for FT4, see Table 2) as
additional covariates to the basic model, and removing those from
the test data set. When lead SNPs were not available, the best
proxies (r2.0.8) were included. We then performed a meta-analysis
on the conditional GWAS results, using the same method and filters
as described above. We used the standard genome-wide significance
cutoff (P,561028) to declare a significant secondary association.
Gender-specific analysis
To identify sex-specific effects, each study performed GWA
analyses for each gender separately, using the same covariates and
transformation as in the basic model (with the exception of gender
covariate). We then performed a meta-analysis on association
results using the same method and filters described for the primary
analysis. To evaluate sex-specific differences we tested heteroge-
neity between effect sizes as described above. False-discovery rates
(FDRs) on the 26 associated SNPs were calculated with R’s
p.adjust() procedure via the method of Benjamini and Hochberg
[24].
Variance explained
The variance explained by the strongest associated SNPs was
calculated, for each trait and in each cohort, as the difference of
R2 adjusted observed in the full and the basic models, where the
full model contains all the independent SNPs in addition to the
covariates. The estimates from each cohort were combined using a
weighted average, with weights proportional to the cohort sample
size.
Extreme phenotype analysis
To evaluate the impact of the detected variants with clinically
relevant TSH levels, we compared the allele frequencies observed
in different categories of individuals in a case-control approach.
Specifically, we compared individuals in the upper and lower TSH
tails (individuals with TSH .4 mIU/L and TSH ,0.4 mIU/L,
respectively, whom were excluded for the GWAS analyses), as well
as individuals in each tail with those in the normal TSH range. In
the first case, individuals in the lower tail were considered controls
and those in the upper tail cases. In the other two cases, we defined
individuals in the normal range as controls and individuals on the
two tails cases. To avoid sources of bias, individuals taking thyroid
medication and/or with thyroid surgery were excluded. Only
unrelated individuals were selected from the family-based cohort
SardiNIA, while GEE correction was applied to the TwinsUK
dataset. Results from single cohorts were then meta-analyzed. We
first assessed the global impact of the 20 TSH- and 6 FT4-
associated variants by defining a genotype-risk score (GRS) for
each individual as the weighted sum of TSH- and FT4-elevating
alleles, with weights proportional to the effect estimated in the
meta-analysis. For each comparison, we then calculated quartiles
from the global distribution (cases+controls) of the genotype score
and used quartile 1 as the baseline reference to compare the
Figure 6. Forest plot of SNPs with gender-specific effects. Squares represent the estimated per-allele beta-estimate for individual studies (a)
and in males and females separately (b). The area of the square is inversely proportional to the variance of the estimate. Diamonds represent the
summary beta estimates for the subgroups indicated. Horizontal lines represent 95% confidence intervals. In b, red and blue dotted lines represent,
respectively, females and males.
doi:10.1371/journal.pgen.1003266.g006
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Table 5. Candidate genes at newly discovered loci for TSH and FT4 levels.
SNP Region Gene Position Trait Function
rs753760 6q26 PDE10A intron 1 TSH Encodes a dual specificity phosphodiesterase abundant in the thyroid, which
can hydrolyze both cAMP and cGMP to the corresponding nucleoside 59
monophosphate, but has higher affinity for cAMP, and is more efficient with
cAMP as substrate. This gene was previously suggestively associated with TSH
levels and hypothyroidism and linkage has been observed over this gene in
families with individuals reaching the clinical criteria for sub-clinical and clinical
thyroid disorders [13,34]. The top SNP is only weakly correlated with previously
reported variants (r2 = 0.449 with rs2983521 and r2 = 0.184 with rs9347083),
but is a perfect proxy of a SNP recently reported in association with TSH [32].
rs9472138; rs11755845 6p12 VEGFA intergenic TSH/FT4 Encodes a growth factor implicated in angiogenesis, which acts as an
important regulator of both benign and malignant processes in the thyroid
[62]. Angiogenesis is particularly critical for thyroid function, as the local
microvasculature exerts an essential role in the continuous supply of iodine,
the key element of thyroid hormone synthesis. In response to a reduction in
intracellular iodine concentration, thyrocytes rapidly release angiogenic
signals, including an increase in VEGFA expression and secretion [63,64].
Notably, thyroid hormone stimulation in rat brain has been shown to induce
VEGFA upregulation [65], which is consistent with the nominal association of
the VEGFA locus with FT4 levels observed in this study. The two independent
signals, rs9472138 and rs11755845, associated with TSH levels map 40 kb
downstream of VEGFA, which is the nearest gene in the region. SNPs in this
region were recently reported in association with TSH levels (r2 = 0.874 and
r2 = 0.947) [32].
rs13015993 2q33-36 IGFBP5 intergenic TSH It belongs to a protein family that interacts with insulin-like growth factors
(IGFs) and plays a major role in regulating cell proliferation, differentiation,
apoptosis and transformation. IGFBP5 is significantly over expressed in thyroid
papillary carcinoma [54,66]. Studies in vitro showed that TSH, through cAMP,
inhibits IGFBP5 transcription, whereas enhanced production of IGFBP5 is
correlated with inhibition of thyroid function [67];[68]. In addition, IFGBP5 has
been found up-regulated in response to thyroid hormone in bone, where it
interacts with the growth hormone/insulin-like growth factor (GH/IGF) system
to contribute to bone formation [69], suggesting that thyroid hormone may
potentate the effect of IGF-1 at the receptor level. The top SNP maps about
60 kb upstream of IGFBP5. A proxy of this SNP has been recently found
associated with TSH and FT4 levels (rs737308, r2 = 0.927) [32].
rs9915657 17q23 SOX9 39UTR TSH Encodes a transcription factor involved in chondrocyte differentiation and
male sex determination, although other specific functions are known. The TA
domain of SOX9, which is expressed both in the pituitary and in the thyroid,
has been reported to interact with a component of the thyroid hormone
receptor complex (TRAP230) [70]. How this interaction could affect TSH levels
is at present unclear. The top SNP maps 5 kb downstream of SOX9, which is
the nearest gene in the region.
rs334699 1p31.3-p31.2 NFIA intron 3 TSH Encodes a member of the NF1 (nuclear factor 1) family of transcription factors.
NFI proteins have been implicated in regulating developmental processes by
their specific expression pattern during embryonic development and by
analysis of NFI-deficient mice [71]. In addition, they play crucial roles in the
transcription of many cellular genes. Members of this family, including NFIA,
have been shown to interact with thyroid transcription factor 1 (TTF1) [72], a
transcription factor essential for thyroid-specific gene expression [73]. The top
SNP maps in intron 3 of the gene. A proxy of this SNP has been recently found
associated with TSH levels (rs334725, r2 = 1) [32].
rs10519227 15q21.2 FGF7 intron 2 TSH Encodes a member of the fibroblast growth factor (FGF) family. FGF family
members are involved in a variety of biological processes, including embryonic
development, cell growth, morphogenesis, tissue repair, tumor growth and
invasion. FGF signals play a role in the development of the thyroid gland and
mice deficient for corresponding receptors show thyroid agenesis [74]. The top
SNP maps in intron 2 of FGF7. A proxy of this SNP has been recently associated
by GWAS with thyroid volume and goiter (rs4338740, r2 = 0.874) [36].
rs17723470 11p11 PRDM11 intron 2 TSH Encodes a member of the family of PR-domain genes involved in human
cancers [75]. The function of PRDM11 and its correlation with TSH levels is
unclear; however the association with low TSH values in the extreme
phenotype analysis supports a role of this gene in this trait. The top SNP maps
in intron 2 of the gene and is moderately correlated with a SNP associated with
TSH levels (rs7128207, r2 = 0.55) [32].
rs17776563 15q25.3 MIR1179 intergenic TSH Encodes a microRNAs (miRNAs), which are short non-coding RNAs involved in
post-transcriptional regulation of gene expression in multicellular organisms
by affecting both the stability and translation of mRNAs. The associated SNP
maps about 30 kb upstream of the gene, which is the nearest gene in the
region.
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Table 5. Cont.
SNP Region Gene Position Trait Function
rs4804416 19p13.3-13.2 INSR intron 2 TSH Encodes the insulin receptor precursor, which is post-translationally cleaved
after removal of the precursor signal peptide into two chains (alpha and beta)
that are covalently linked. Binding of insulin to the insulin receptor (INSR)
stimulates glucose uptake. Two transcript variants encoding different isoforms
have been found for this gene. INSR isoforms appear overexpressed in thyroid
tumors, where they interact with insulin homolog IGFs (I and II), which act as
potent mitogenic and antiapoptotic factors in a variety of human
malignancies, and supporting a specific role of the GH/IGF pathway in thyroid
function. The top SNP maps in intron 2 of the INSR, and is moderately
correlated (rs10420008, r2 = 0.435) with a variant recently associated with TSH
levels [32].
rs657152 9q34.2 ABO intron 1 TSH Encodes proteins related to the blood group system, ABO, which determines
the individual blood group. The associated SNP is in intron 1 of the gene and is
a tag of the O blood group allele, caused by a deletion of guanine-258 near the
N-terminus of the protein which results in a frameshift and translation of an
almost entirely different protein. The correlation of TSH with ABO blood
groups is currently unclear. ABO has been found associated with several
phenotypes, including serum levels of different molecules [76]. It was reported
that serum levels of TSH vary in individuals with ABO blood types, and that
blood group O may be associated with hyperthyroidism [77].
rs11624776 14q31 ITPK1 intergenic TSH Encodes the enzyme inositol 1,3,4-trisphosphate 5/6-kinase, which catalyzes
the rate-limiting step in the formation of higher phosphorylated forms of
inositol in mammalian cells. ITPK1 plays a pivotal role in inositol metabolism
and mice producing reduced levels of ITPK1 develop neural tube defects [78].
Its role in the regulation of TSH levels is at present unclear. Of note, inositol
phosphates/Ca2+ cascades mediates TSH action on thyroid hormone synthesis
[79] The associated SNP is located about 15 kb upstream of the gene, which is
the nearest gene in the region.
rs7825175 8p12 NRG1 intron 2 TSH Encodes neoregulin 1, a glycoprotein that interacts with the NEU/ERBB2
receptor tyrosine kinase to increase its phosphorylation on tyrosine residues.
NRG1 is a signaling protein that mediates cell-cell interactions and plays critical
roles in the growth and development of multiple organ systems. Its gene
dysregulation has been linked to cancer, schizophrenia and bipolar disorder.
The associated SNP maps in intron 2 of the gene and is only weakly correlated
with a variant recently associated with TSH levels and thyroid cancer risk
(rs2439302, r2 = 0.257) [32].
rs1537424 14q13.3 MBIP intergenic TSH Encodes MAP3K12/MUK-binding inhibitory protein, a MAP3K regulator during
osmolarity sensing and stress signaling that localizes in either the cytoplasm or
nucleus [80]. SNPs in this locus have been recently reported as associated with
TSH levels and thyroid cancer risk [32]. The top associated SNP maps at about
190 kb downstream of MBIP, which is the nearest gene in the region. Recently,
a long, intergenic, noncoding RNA gene (lincRNA) named Papillary Thyroid
Carcinoma Susceptibility Candidate 3 (PTCSC3) has been mapped 3.2 kb
downstream of rs944289 (r2 = 0.708 with our top SNP), whose expression is
strictly thyroid specific and acts as a PTC tumor suppressor gene [81].
rs9497965 6q24.3 SASH1 intergenic TSH Encodes a member of the SLY-family of signal adapter proteins and is a
candidate tumor suppressor in breast and colon cancer. However, the
biological function of SASH1 and its involvement in malignant transformation
remain largely unknown. Of note, SASH1 has been identified as a downstream
target of the insulin/IGF1/PI 3-kinase signaling pathway [82], which appears
implicated in TSH levels in the current study. The associated SNP is located
about 130 kb upstream of SASH1, which is the nearest gene in the region.
rs1571583 9p24.2 GLIS3 intron 2 TSH Encodes a nuclear protein with five C2H2-type zinc finger domains, which is a
member of the GLI-similar zinc finger protein family. GLIS3 functions as both a
repressor and activator of transcription and is specifically involved in the
development of pancreatic beta cells, the thyroid, eye, liver and kidney.
Mutations in this gene have been associated with neonatal diabetes and
congenital hypothyroidism (NDH) [52]. The top SNP at this locus maps in intron
2 of the gene.
rs7860634 9q34.3 LHX3 intron 6 FT4/TSH Encodes a transcription factor with an essential role in pituitary development
[30]. Mutations in LHX3 cause the combined pituitary hormone deficiency-3
(CPHD3) syndrome (OMIM #221750), characterized by a complete deficit in
growth hormone, prolactin, gonadotropin, and TSH, a rigid cervical spine
leading to limited head rotation, as well as an extended spectrum with variable
sensorineural hearing loss and ACTH deficiency [31,42,43], which is consistent
with its association also with TSH levels observed in this study. This locus has
been also recently associated with height in Japanese [44] The top SNP maps
in intron 6 of the gene.
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number of cases and controls in the other quartiles. In addition, for
TSH-associated variants we conducted single SNP comparisons.
GRS quartile and single SNP analyses were performed by each
study separately. Cohort specific results were then meta-analyzed
for both the GRS score and single SNP results only if they had at
least 50 cases and 50 controls. Specifically, cohorts included were:
CHS, Lifelines, PROSPER, RS, SardiNIA and TwinsUK.
Bivariate analysis
Bivariate analysis was carried out with the software poly [26] in
the SardiNIA cohort using the same individuals included in the
GWAS and considering the same covariates and transformation
for TSH and FT4 levels.
Web resources
The URLs for data presented herein are as follows:
METAL, http://www.sph.umich.edu/cgs/abecasis/metal
MACH, http://www.sph.umich.edu/csg/abecasis/MACH/
IMPUTE, https://mathgen.stats.ox.ac.uk/impute/impute.html
LocusZoom, http://csg.sph.umich.edu/locuszoom/
HapMap, http://www.hapmap.org
Online Mendelian Inheritance in Man (OMIM), http://www.
omim.org/
Supporting Information
Figure S1 Manhattan plots from meta-analysis results of serum
TSH (panel A) and FT4 (panel B) levels. SNPs are plotted on the x
axis according to their position (build 36) on each chromosome
against association with TSH (A) and FT4(B) on the y axis (shown as
–log10 P value) in. The loci highlighted in green are those that
reached genome-wide significance (P,561028). In each panel,
quantile-quantile plots obtained with all SNPs (red dots) and after
removal of SNPs within associated regions (blue dots) are also shown.
The gray area corresponds to the 90% confidence region from a null
distribution of P values (generated from 100 simulations).
(TIF)
Figure S2 Panel A. Manhattan plots from meta-analysis results of
serum TSH and FT4 levels for men and women separately are
shown as indicated. SNPs are plotted on the x axis according to their
position (build 36) on each chromosome; association with TSH and
FT4 is indicated on the y axis (as –log10 P value). Signals reaching
Table 5. Cont.
SNP Region Gene Position Trait Function
rs7045138 9q22 FOXE1 intergenic FT4 Encodes a transcription factor crucial for thyroid morphogenesis. Mutations in
FOXE1 cause the Bamforth-Lazarus syndrome (MIM #241850), characterized by
thyroid dysgenesis with neonatal hypothyroidism, cleft palate, choanal atresia
and spiky hair [40,41]. In addition, FOXE1 is a susceptibility locus for thyroid
cancer [19,83–85]. The top SNP maps 25 kb upstream of FOXE1 and is also
associated in our study with FT4 levels. SNPs in the FOXE1 locus were
previously associated with FT4 levels in a recent candidate gene analysis
(rs1443434, r2 = 0.776) [18], as well as by GWAS with both low serum TSH and
T4 levels (rs965513, r2 = 1) [19], and hypothyroidism (rs7850258, r2 = 0.625)
[20].
rs716822 4q33 AADAT intron 4 FT4 AADAT catalyzes the synthesis from kynurenine (KYN) of kynurenic acid
(KYNA), which is implicated in the pathophysiology of several diseases of the
central nervous system involving inflammation-induced brain injury [46–49].
The KYN pathway has been associated with the induction of proinflammatory
cytokines in the brain, which are known to activate the hypothalamo-pituitary-
adrenal (HPA)-axis, involved in stress response and affecting the HPT-axis and
thyroid function, including FT4 levels [45]. The top SNP maps in intron 4 of the
gene.
rs7240777 18q22 NETO1/FBXO15 intergenic FT4 The top SNP maps in a gene desert region, with NETO1 located about 550 kb
upstream and FBXO15 about 500 kb downstream. None of these genes has a
clear role in thyroid function. NETO1 is expressed in brain and encodes a
predicted transmembrane protein containing two extracellular CUB domains
followed by a low-density lipoprotein class A (LDLa) domain. A similar gene in
mice plays a critical role in spatial learning and memory by regulating the
function of synaptic N-methyl-D-aspartic acid receptor complexes in the
hippocampus. FBOX15 encodes a member of the F-box protein family
characterized by an approximately 40-amino acid F-box motif. SCF complexes,
formed by SKP1 (MIM#601434), cullin (see CUL1; MIM#603134), and F-box
proteins, act as protein-ubiquitin ligases. F-box proteins interact with SKP1
through the F box, and they interact with ubiquitination targets through other
protein interaction domains.
rs6499766 16q12.2 LPCAT2/
CAPNS2
intron 11 FT4 LPCAT2 encodes a member of the lysophospholipid acyltransferase family. The
enzyme may function to catalyze both the biosynthesis of platelet-activating
factor and of glycerophospholipid precursors from arachidonyl-CoA and
lysophosphatidylcholine. The encoded protein may function in membrane
biogenesis and production of platelet-activating factor in inflammatory cells.
The associated SNP maps in intron 11 of the gene, and is also near CAPNS2,
which is contained in the LPCAT2 gene. None of these genes has a clear role in
thyroid function. Of note, calpain subunit genes (CAPNS1 and CAPNS2) play
important functions in mammalian reproduction [25].
The table lists genes of interest in the novel associated regions. For each associated region, the reported gene either contains the lead SNP or is in closest physical
proximity with the lead SNP.
doi:10.1371/journal.pgen.1003266.t005
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genome-wide statistical significance in the gender specific analysis
are shown in green. Panel B. Quantile-quantile plots are shown for
all SNPs (red dots) and after removal of SNPs within associated
regions (blue dots).
(TIF)
Figure S3 Ingenuity pathway analysis (IPA) results for candidate
genes in the TSH and FT4 associated loci. A single protein
network connects most of the identified loci.
(PDF)
Table S1 Analysis details andmethods for individual GWAS studies.
(XLS)
Table S2 GWAS results of top SNPs for single cohorts. In the
row named ‘‘G/I’’ we report the imputation quality (RSQR or
INFO, according to study specific imputation method) or indicate
with the letter ‘‘G’’ if the SNP was genotyped (G).
(XLSX)
Table S3 Heterogeneity analysis of South European vs North
American cohorts. The table shows the results of the two meta-
analyses carried out in studies of South Europe and North America
individuals, respectively. For each meta-analysis, we report the
frequency of the effect allele (FreqA1), the effect size and the
corresponding standard error (Effect, StdErr), the combined
association pvalue (P), the pvalue for heterogeneity between studies
(Het P), and the number of samples analyzed (N). The last two
columns report the pvalue for differences of the effect size estimated
in the two groups, and the total number of samples analyzed.
(DOC)
Table S4 Association results for TSH and FT4 overlapping loci
and their involvement in the negative feedback loop. The table
shows the association results for all independent TSH (top panel)
and FT4 (bottom panel) associated SNPs with FT4 and TSH
levels, respectively. Effect sizes are standardized, so they represent
the estimated phenotypic change, per each copy of the effect allele,
in standard deviation units.
(DOC)
Table S5 Genotype risk score for TSH alleles in pregnant women.
(DOC)
Table S6 Association between TSH genetic risk score in
pregnant women and subclinical hypothyroidism in pregnancy.
Genotype risk score (GRS) was calculated in women with TSH
level above reference range (.4.21 mIU/L) versus TSH level
#4.21 mIU/L. Notably, excluding the 2 women with overt
hypothyroidism (TSH.4.21 mIU/L and FT4 ,9.13 pg/L), the
results were essentially unchanged: Effect = 0.163, StdErr = 0.080,
P = 0.043, OR=1.18. StdErr, standard error, OR, odds ratio.
(DOC)
Table S7 Association of SNPs reported by Gudmundsson and
colleagues in our dataset. The table shows the association results
for SNPs reported by Gudmundsson and colleagues [32] with
TSH and FT4 levels available in our data-set. When the same
marker was not available, we reported a proxy (r2.0.8) and the
relative r2. StdErr, standard error. Loci reaching genome-wide
significance in our data set with either the same SNP or a proxy
are highlighted in bold.
(DOC)
Text S1 Supplemental acknowledgments and funding informa-
tion, cohort description, phenotyping, genotyping, analysis
methods, supplemental references.
(DOC)
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